08.12.25 -- STREAM Edition: Cell And Gene Therapy Formulation And Fill Platform

Explore how automated formulation and filling systems enable robust, scalable, and cost-effective cell and gene therapy manufacturing—from small-scale development to full end-to-end commercial production.

Streamline CAR T cell therapy manufacturing with an end-to-end solution featuring two automated systems that optimize every stage from cell isolation to final therapeutic dose.

Focusing on critical parameters such as cell culture conditions, viral vector yield, and downstream purification strategies, can drive the success of scale-up and scale-down models for AAV production.

Our findings provide critical insights into refining ASO extraction protocols, which can enhance the accuracy of downstream analyses and support further research into ASO-based therapeutics.

As lead partner for CAR-TCR 2023, we opened with a plenary on CDMO value in autologous cell therapy, highlighting a decade-long partnership behind two gene therapy launches in 2022.

Aaron Vernon from Quell Therapeutics joins to explore building robust cell therapy manufacturing, focusing on overcoming bottlenecks, smart facility design, and the crucial role of digitalization.

Whether you are a researcher, scientist, or industry professional, this video will provide valuable insights into our large volume liquids manufacturing capabilities.

Cell & Gene: The Podcast Host, Erin Harris, talks to Orca Bio CEO and Co-Founder Nathaniel Fernhoff as he recounts the company’s origins and evolution, tracing its roots to pioneering stem cell research at Stanford University and Dr. Irv Weissman's lab.